Versartis Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
-
-
-
-
40,000.00
Cost of Goods Sold (COGS) incl. D&A
-
107.00
194.00
215.00
-
Gross Income
-
107.00
194.00
215.00
-
SG&A Expense
19,266.00
46,006.00
82,314.00
96,105.00
124,171.00
EBIT
19,283.00
46,113.00
82,508.00
96,320.00
84,482.00
Unusual Expense
-
11,839.00
-
80.00
-
Non Operating Income/Expense
913.00
307.00
113.00
316.00
1,591.00
Interest Expense
128.00
-
-
-
-
Pretax Income
18,497.00
57,513.00
82,177.00
95,570.00
85,226.00
Income Tax
-
-
-
247.00
247.00
Consolidated Net Income
18,497.00
57,513.00
82,177.00
95,817.00
84,979.00
Net Income
18,497.00
57,513.00
82,177.00
95,817.00
84,979.00
Net Income After Extraordinaries
18,497.00
57,513.00
82,177.00
95,817.00
84,979.00
Net Income Available to Common
18,497.00
83,072.00
82,177.00
95,817.00
84,979.00
EPS (Basic)
0.76
4.39
2.84
3.11
2.41
Basic Shares Outstanding
24,194.80
18,921.50
28,964.00
30,784.00
35,228.00
EPS (Diluted)
0.76
4.39
2.84
3.11
2.41
Diluted Shares Outstanding
24,194.80
18,921.50
28,964.00
30,784.00
35,228.00
EBITDA
19,266.00
46,006.00
82,314.00
96,105.00
84,171.00
Non-Operating Interest Income
1.00
132.00
218.00
514.00
847.00
Preferred Dividends
-
25,559.00
-
-
-

About Versartis

View Profile
Address
1020 Marsh Roade
Menlo Park California 94025
United States
Employees -
Website http://www.versartis.com
Updated 09/14/2018
Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L.